EGFR and non-small cell lung carcinoma: However, PLK1 inhibitors exhibited broad-spectrum antiproliferative activity in various EGFR-mutant NSCLC and Ba/F3-transformed cell lines, including those with secondary mutations, with average IC50 values ranging from 5 to 10 nM (Fig. 1B and Supplementary Fig. 1A).